Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23813670 | 0.88 | SLC28A1 (0.67) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18503505 | 0.82 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18503427 | 0.81 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23813658 | 0.80 | SLC28A1 (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25101231 | 0.80 | SLC28A1 (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18464354 | 0.79 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18465153 | 0.79 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL30937385 | 0.79 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9144523 | 0.78 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8887620 | 0.78 | SLC28A1 (0.67) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | SLC28A1 2316/4885SLC28A2 3879/4885SLC29A1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.